Daclatasvir - Bristol-Myers Squibb
Alternative Names: BMS-790052; Daklinza; DCVLatest Information Update: 05 Nov 2023
At a glance
- Originator AmeriCares; Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; Vertex Pharmaceuticals
- Class Antivirals; Biphenyl compounds; Carbamates; Imidazoles; Pyrrolidines; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis C
Most Recent Events
- 29 Dec 2022 No development reported - Phase-II for Hepatitis C (Combination therapy, In adolescents, In children, Treatment-naive, Treatment-experienced) in Poland, Australia (PO)
- 17 Sep 2020 Bristol-Myers Squibb terminates a phase II trial in Hepatitis C (Combination therapy, In adolescents, In children, Treatment-naive, Treatment-experienced) in Australia, Poland, Germany, Spain and Taiwan, due to change in business objectives (NCT03487848) (EudraCT2017-003338-94)
- 07 Jun 2018 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in Egypt (PO)